SPOTLIGHT: Kosan touts Hsp90 results

Sweden's Kosan Biosciences says that preliminary results of a Phase I trial of its experimental heat shock protein 90 inhibitor showed signs of antiocancer activity and tolerability. Several biotechs are racing to develop Hsp90 inhibitors, including Infinity Pharmaceuticals, which researchers believe will ultimately lead to a treatment that can kill of cancer cells. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.